Taysha Gene Therapies (TSHA) Operating Expenses (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Operating Expenses of $43.5 million for Q1 2026, up 28.71% sequentially from $33.8 million in Q4 2025, and up 83.31% YoY from $23.7 million in Q1 2025.
Taysha Gene Therapies (TSHA) Operating Expenses (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Operating Expenses for 7 years, with the latest figure at $43.5 million in Q1 2026.
- Quarterly Operating Expenses rose 83.31% year-over-year to $43.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140.0 million (up 46.21% YoY) and the FY2025 annual result came in at $120.3 million, up 20.52% from the prior year.
- Operating Expenses advanced to $43.5 million in Q1 2026 per TSHA's latest filing, from $33.8 million in the prior quarter.
- Over five years, Operating Expenses peaked at $56.5 million in Q4 2022 and troughed at $19.8 million in Q4 2023.
- A 5-year average of $30.4 million and a median of $27.7 million in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2026: Operating Expenses slumped 64.85% in 2023, then surged 83.31% in 2026.
- Over 5 years, Operating Expenses stood at $56.5 million in 2022, then plunged by 64.85% to $19.8 million in 2023, then grew by 10.6% to $22.0 million in 2024, then surged by 53.89% to $33.8 million in 2025, then rose by 28.71% to $43.5 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $43.5 million, $33.8 million, and $34.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | 47.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.35 Mn |
| Mar 31, 2026 | 43.49 Mn |
| Dec 31, 2025 | 33.79 Mn |
| Sep 30, 2025 | 34.02 Mn |
| Jun 30, 2025 | 28.74 Mn |
| Mar 31, 2025 | 23.72 Mn |
| Dec 31, 2024 | 21.95 Mn |
| Sep 30, 2024 | 27.69 Mn |
| Jun 30, 2024 | 22.41 Mn |
| Mar 31, 2024 | 27.74 Mn |
| Dec 31, 2023 | 19.85 Mn |
| Sep 30, 2023 | 21.00 Mn |
| Jun 30, 2023 | 25.78 Mn |
| Mar 31, 2023 | 21.27 Mn |
| Dec 31, 2022 | 56.47 Mn |
| Sep 30, 2022 | 25.46 Mn |
| Jun 30, 2022 | 33.37 Mn |
| Mar 31, 2022 | 49.65 Mn |
| Dec 31, 2021 | 49.72 Mn |
| Sep 30, 2021 | 50.68 Mn |